Delayed treatment with aminoguanidine (AG), a relatively selective inhibitor of inducible nitric oxide synthase, ameliorates brain damage produced by occlusion of the rat's middle cerebral artery (MCA). We investigated whether the protection exerted by AG is dose-dependent and whether it is associated with improved neurologic outcome. We also studied the effect of the timing of administration of AG relative to the induction of cerebral ischemia. Halothane-anesthetized sponta neously hypertensive rats underwent permanent MCA occlu sion distal to the lenticulostriate branches. Neurologic deficits were assessed daily by the postural reflex test and beam bal ance test. Infarct volume was determined in thionin-stained sections 96 hours after ischemia and values corrected for swell ing. Treatment with AG (intraperitoneally, twice daily), starting 24 hours after MCA occlusion, decreased neocortical infarct volume in comparison to vehicle-treated rats. After correction for swelling, the decrease was 8 ± 12% at 50 mg/kg (n = 8; P > .05; analysis of variance), 25 ± 13% at 100 mg/kg (n = 7; P We have previously shown that administration of ami noguanidine (AG), a compound that inhibits inducible nitric oxide synthase (iNOS), decreases the infarct result ing from transient or permanent occlusion of the middle cerebral artery (MCA) in rats Iadecola et al., 1995a; Zhang et al., 1996) . AG blocks the increase in iNOS activity that follows focal cerebral isch-Abbreviations used: AG, aminoguanidine; AGE, advanced glycation end-product; eNOS, endothelial nitric oxide synthase; HSD, honestly significant difference; iNOS, inducible nitric oxide synthase; MCA, middle cerebral artery; SHR, spontaneously hypertensive rats.
Summary: Delayed treatment with aminoguanidine (AG), a relatively selective inhibitor of inducible nitric oxide synthase, ameliorates brain damage produced by occlusion of the rat's middle cerebral artery (MCA). We investigated whether the protection exerted by AG is dose-dependent and whether it is associated with improved neurologic outcome. We also studied the effect of the timing of administration of AG relative to the induction of cerebral ischemia. Halothane-anesthetized sponta neously hypertensive rats underwent permanent MCA occlu sion distal to the lenticulostriate branches. Neurologic deficits were assessed daily by the postural reflex test and beam bal ance test. Infarct volume was determined in thionin-stained sections 96 hours after ischemia and values corrected for swell ing. Treatment with AG (intraperitoneally, twice daily), starting 24 hours after MCA occlusion, decreased neocortical infarct volume in comparison to vehicle-treated rats. After correction for swelling, the decrease was 8 ± 12% at 50 mg/kg (n = 8; P > .05; analysis of variance), 25 ± 13% at 100 mg/kg (n = 7; P We have previously shown that administration of ami noguanidine (AG), a compound that inhibits inducible nitric oxide synthase (iNOS), decreases the infarct result ing from transient or permanent occlusion of the middle cerebral artery (MCA) in rats Iadecola et al., 1995a; Zhang et al., 1996) . AG blocks the increase in iNOS activity that follows focal cerebral isch-< .05), 30 ± 16% at 200 mg/kg (n = 7; P < .05) and 32 ± 9% at 400 mg/kg (n = 5; P < .05). Twenty-four hours after induc tion of ischemia neurologic deficits scores did not differ be tween treated and untreated rats (P > .05). However, from 48 to 96 hours after ischemia, neurologic deficits improved signifi cantly in rats treated with AG (100 to 400 mg/kg) compared to rats in which vehicle was administered (P < .05). The decrease in neocortical infarct volume was greatest when AG (100 mg/ kg; twice daily) was administered 12 (26 ± 17%; n = 9) or 24 hours (25 ± 13; n = 7) after MCA occlusion. The findings show that AG decreases ischemic brain damage dose dependently and improves neurologic recovery. Delayed treat ment with AG may be a therapeutic strategy to selectively target the evolution of ischemic damage that occurs in the post-ischemic period. Key Words: Cerebral ischemia Aminoguanidine-Rats-Middle cerebral artery occlusion Neurologic deficits. emia (Iadecola, et al., 1995a) . Furthermore, its protective effect is counteracted by the nitric oxide precursor L arginine but not by D-arginine (Iadecola, et al., 1995a) . These observations indicate that the decrease in ischemic damage by AG is, at least in part, related to iNOS inhi bition.
The decrease in ischemic damage afforded by AG is notable in that it occurs even when the drug is adminis tered 24 hours after MCA occlusion (Iadecola, et al., 1995a) . This finding indicates that brain tissue can be rescued from infarction many hours after induction of ischemia. Therefore, treatment with AG may be effective in preventing the delayed evolution of the damage that occurs in the post-ischemic period. Considering that most stroke patients reach medical attention many hours after the onset of symptoms (Alberts et al., 1990) , AG would be a welcome addition to current therapeutic op tions available for cerebral ischemia. However, several important questions regarding the protective effect of AG remain to be addressed. The concentration of AG resulting in maximal protection and the optimal timing of administration of AG relative to the induction of isch emia have not been established. In addition, it remains to be determined whether the decrease in brain damage, assessed histologically, is associated with an improve ment in the neurologic outcome. Therefore, considering the potential therapeutic value of AG in stroke, it would be important to obtain data to clarify these issues.
In the present study we used a rat model of focal cerebral ischemia to better characterize the protective effect exerted by AG. First, we sought to identify the dose of AG resulting maximal protection. Second, we tested the hypothesis that the protective effect of AG is associated with a better neurologic recovery after stroke. Third, we sought to determine the optimal time for AG administration after cerebral ischemia. We found that administration of AG results in a dose-related decrease in cerebral ischemic damage that is associated with a cor responding improvement of neurologic deficits. The greatest decrease in ischemic damage was observed when AG was administered 12 to 24 hours after isch emia. The data show that delayed administration of AG improves both histologic damage and neurologic out come after cerebral ischemia and provide additional evi dence in support of the hypothesis that AG is a poten tially useful agent for the treatment of the late stages of cerebral ischemia.
METHODS
Methods for MCA occlusion with monitoring of physiologic parameters and for determination of infarct size have been de scribed in detail in previous publications (Iadecola, et a!., 1995a,b; Zhang and Iadecola, 1992) and will only be summa rized.
General surgical procedures
Studies were approved by the Institutional Animal Care and Use Committee and were conducted on 60 male spontaneously hypertensive rats (SHRs; Harland) weighing 300 to 350 g. SHRs were used because of the well-known reproducibility of focal cerebral ischemic damage in this strain (Ginsberg and Busto, 1989) . Under halothane anesthesia (induction: 5%; maintenance: 1 %, in an oxygen-nitrogen mixture), the left femoral artery was cannulated. Body temperature was main tained at 37 ± O. SOC by a thermostatically controlled infrared lamp (YSI, mod. 73A-TA, Yellow Springs, OH). The arterial catheter was connected to a pressure transducer for recording of mean arterial pressure. Serum glucose was measured by a glu cose analyzer (Beckman) and arterial blood gases were moni tored by a blood gas analyzer (ClBA-Corning, mod. 178, Med field, MA). The arterial catheter was tunneled under the skin and exteriorized at the level of the tail. The catheter was used for recording of arterial pressure and for determination of se rum glucose, hematocrit, and arterial blood gases at different times after MCA occlusion.
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Middle cerebral artery occlusion and measurement of infarct volume
Procedures for MCA occlusion and for determination of in farct volume are similar to those published previously (Zhang and Iadecola, 1992) . Briefly, a 2-mm hole was drilled at a site superior and lateral to the left foramen ovale to expose the left MCA. The MCA was elevated and cauterized distal to the origin of the lenticulostriate arteries and medial to the inferior cerebral vein (Zhang and Iadecola, 1992) . Animals were then returned to their cages and monitored until they recovered con sciousness. All rats regained consciousness rapidly and did not exhibit clinical evidence of seizures. After consciousness was regained, rats did not exhibit behavioral evidence of pain or discomfort.
Rats were killed 96 hours after induction of ischemia and their brains were removed and processed for determination of infarct volume. The forebrain was frozen in cooled isopentane (-30DC). Coronal forebrain sections (thickness 30 /-Lm) were cut serially in a cryostat. One section every 300 /-Lm was col lected and stained with thionin. As described in detail else where (Zhang and Iadecola, 1992) , infarct volume was deter mined using an image analyzer (Imaging Research Inc., MClD, St. Catharines, Ontario, Canada). Infarct volume in cerebral cortex was corrected for swelling according to the method of Lin et a1. (Lin et aI., 1993) , as previously described (Iadecola, et aI., 1995a; Zhang and Iadecola, 1994) .
Neurologic evaluation
Examinations were performed before MCA occlusion and every day thereafter up to 96 hours after MCA occlusion. The examiner was blinded to the treatment groups. Postural reflexes were tested as previously described (Bederson et al., 1986) . Rats were suspended by the tail 1 m above the floor and slowly lowered while observing their posture. Rats were then placed on a flat surface and gently pushed from side to side. Deficits were scored as follows: 0, no deficit; 1, forelimb flexion while suspended by the tail; 2, decreased resistance to lateral push. Rats were also evaluated by the beam balance test (Feeney et aI., 1982) . Animals were required to walk on a narrow beam (width: 3/4"; length: 10") for 60 seconds. Deficits were graded based on the scale by Clifton et a1. (Clifton et aI., 1991) : 1, steady posture with paws on top of beam; 2, paws on side of beam or wavering; 3, one or two limbs slip off beam; 4, three limbs slip off beam; 5, rat attempts to balance with paws on beam but falls; 6, rat drapes over beam, then falls; 7, rat falls off the beam without attempting to stay on.
Experimental protocol
Rats were returned to their cages after insertion of the femo ral arterial catheter and, when they fully recovered from the anesthesia, baseline arterial pressure, blood gases, serum glu cose, rectal temperature, and hematocrit were measured. Rats were then re-anesthetized for MCA occlusion.
AG dose-response study. The MCA was occluded as de scribed above, and treatments were started 24 hours later. AG hemisulfate (Sigma) was administered intraperitoneally at 10 AM and 6 PM at doses of 50 mg/kg (n = 8), 100 mg/kg (n = 7), 200 mg/kg (n = 7), or 400 mg/kg (n = 5) in I mL of saline. The dose range was selected on the basis of our previous ex perience with AG (Iadecola, et aI., 1995a) . The drug was ad ministered for 3 consecutive days. One group of rats (n = 9) received vehicle (saline; I mL intraperitoneally) at 10 AM and 6 PM. The pH of the solutions injected was adjusted to 7.0 using NaOH. Arterial pressure, rectal temperature, and serum AMINOGUANIDINE AND CEREBRAL ISCHEMIC DAMAGE [[09 glucose were measured daily at 9 AM, 11 AM, S PM, and 7 PM as previously described (Iadecola, et aI., 1995a) . Rats were not restrained during these measurements. To limit the amount of blood loss, arterial hematocrit and blood gases were measured before injection and 24, 48, 72, and 96 hours after ischemia.
Ninety-six hours after induction of ischemia, rats were killed for determination of infarct volume.
Effect of timing of administration of AG relative to MCA occlusion. Three groups of rats were studied. In one group (n = 6), AG (100 mg/kg in 1 mL of saline) was administered intraperitoneally at lOAM and 6 PM starting 6 hours after MCA occlusion. In another group (n = 9), AG was adminis tered at the same dose and frequency starting 12 hours after MCA occlusion. A third group of rats (n = 9) was treated with vehicle (1 mL) at 10 AM and 6 PM. Treatments were continued daily and rats were killed 96 hours after MCA oc clusion for determination of infarct volume. Arterial pressure, blood gases, serum glucose, rectal temperature, and hemato crit were monitored as described above for the dose-response study.
Data analysis
Data in the text, table, and figures are expressed as means ± SD. Comparisons among multiple groups were evaluated by one-way analysis of variance followed by the Tukey-Kramer honestly significant difference (HSD) test as a post hoc mul tiple comparison procedure (Systat Inc.) (Kirk, 1982) . Neuro logic deficits were statistically evaluated by Kruskal-Wallis test followed by post hoc Tukey-Kramer HSD test (Sokal and Rohlf, 1994) . Differences were considered significant at p < .05.
RESULTS

Effect of AG dose on infarct volume and neurologic deficits
In these experiments we studied the relationship be tween dose of AG (50 to 400 mg/kg) and the correspond ing decrease in infarct volume. Treatments were started 24 hours after MeA occlusion. Arterial pressure, rectal temperature, and serum glucose did not differ among the groups studied (P > .05, analysis of variance and Tukey Kramer HSD test) ( Fig. 1) , except for the 400-mg/kg group in which AG produced a mild increase in arterial pressure and a decrease in rectal temperature (32 to 74 hours after MeA occlusion) ( Fig. 1) . Baseline pe02, p02, pH, and hematocrit in the vehicle group were, re spectively, 37 ± 10 mm Hg, 85 ± 5 mm Hg, 7.44 ± 0.04 and 49.6 ± 1.4%. No differences in these variables were noted among the various treatment groups during the course of the study (P > .05). In vehicle-treated rats (n = 9), distal MeA occlusion produced infarcts involving almost exclusively the neocortex ( Table I) . The volume of the infarct and its regional distribution were similar to those previously reported after distal MeA occlusion (Iadecola, et aI., 1995a) . Administration of AG de creased neocortical infarct volume dose-dependently (Table 1) . After correction for ischemic swelling, the decrease in neocortical infarct volume was 8 ± 12% at 50 mg/kg (P > .05 from vehicle; n = 8), 25 ± 13% at 100 I :::
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FIG. 1. Effect of administration of saline (vehicle), or aminogua nidine (AG; 50 to 400 mg/kg) on mean arterial pressure, rectal temperature, and serum glucose. Arterial pressure did not differ among groups (P > .05, analysis of variance and Tukey-Kramer honestly significant difference test), except for the 400-mg/kg group, in which treatment produced a sustained but mild increase in arterial pressure (P < .05). Rectal temperature was increased by 1°C to 1SC after ischemia and did not differ among groups (P > .05), except for the 400-mg/kg group in which the temperature was decreased at some time points, in comparison to vehicle treated rats (P mg/kg (P < .05; n = 7), 30 ± 16% at 200 mg/kg (P < .05; n = 7), and 32 ± 9% at 400 mg/kg (P < .05; n = 5). The volume of tissue swelling did not differ among the groups studied (P > .05) ( Table 1) . The time course of the effect of AG on the neurologic deficits resulting from MeA occlusion is shown in Fig  ure 2 Scores for the postural reflex test and the beam balance test did not differ between treated and untreated rats at 24 hours after MeA occlusion (P > .05, Kruskal Wallis and Tukey-Kramer HSD tests). In rats receiving vehicle, neurologic deficits remained stable throughout the monitoring period (24 to 96 hours after MeA occlu sion; Fig. 2 ). However, in rats treated with AG, the defi cits improved between 24 and 96 hours after MeA oc clusion. The effect was related to the dose of AG and was maximal at 200 to 400 mg/kg (P < .05). The data suggest that AG treatment decreases infarct volume and im proves the neurologic deficits resulting from MeA oc clusion.
Effect of the timing of administration of AG relative to MeA occlusion
In these studies we investigated the relationship be tween the time interval between MeA occlusion and administration of AG (100 mglkg) and the observed de crease in infarct size. As shown in Fig. 3 , arterial pres sure, serum glucose, and rectal temperature did not differ among the groups studied (P > .05). Baseline pC02, p02, pH, and hematocrit in the vehicle group were, re spectively, 42 ± 4 mm Hg, 79 ± 5 mm Hg, 7.41 ± 0.08 and 50.9 ± 1.6%. No differences in these variables were noted among the different groups during the course of the study (P > .05). Administration of AG starting 6 hours after MCA occlusion decreased infarct size by 13 ± 23% (corrected for swelling), a change that did not reach statistical significance (P > .05; n = 6; Table 2 ). Treatments started 12 hours (n = 9) after MCA occlu sion decreased neocortical infarct volume by 26 ± 17% (P < .05) ( served when AG was administered 12 hours after MCA occlusion was identical to that observed when AG was administered 24 hours after MCA occlusion (see 100 mglkg-group of the dose-response study). The volume of tissue swelling did not differ among the groups studied (P > .05). Thcrefore, the protection exerted by AG is greater when the drug is administered 12 or 24 hours than 6 hours after MCA occlusion.
DISCUSSION
We have shown that administration of AG decreases the size of the infarct resulting from MCA occlusion in a dose-dependent fashion and that such a decrease is as sociated with an improvement in neurologic deficits, as 
FIG. 3. Mean arterial pressure, rectal temperature, and serum glucose in rats in which the effect of the timing of aminoguanidine administration on infarct volume was studied. These variables did not differ among the groups of rats. AG, aminoguanidine; MAP, mean arterial pressure; MCAO, middle cerebral artery occlusion.
Mean ± SO. (0) Vehicle (n = 9). (e) AG from 6 hours after MCAO (n = 6). (L',) AG from 12 hours after MCAO (n = 9).
assessed by the postural reflex and beam balance tests. The effect of AG is more marked when the drug is ad ministered 12 to 24 hours rather than 6 hours after MeA occlusion. The observation that AG improves the neuro logic deficits of the animals is of interest because it sug gests that the brain tissue spared from infarction by AG is functional and results in a better neurologic outcome. Although it had previously been shown that AG is ben eficial to the postischemic brain (ladecola, et aI., 1996; Iadeco1a, et aI., 1995a) , the present study extends these observations by identifying the most effective dose (200 to 400 mg/kg) and timing of administration (12 to 24 hours after ischemia). Most importantly, the present Values are mean ± SD. MeAO, middle cerebral artery occlusion. * P < 0.05 from vehicle, analysis of variance and Tukey-Kramer HSD test. study shows that the decrease in histologic damage is reflected in improvement of some of the neurologic defi cits associated with MeA occlusion. These new obser vations provide additional evidence supporting the va lidity of AG as a potential treatment for the late stages of cerebral ischemia.
The effect of AG cannot be a consequence of changes in arterial pressure, blood gases, hematocrit, rectal tem perature, or serum glucose because these variables were carefully monitored and did not differ among the groups studied. In rats treated with the highest dose of AG (400 mg/kg) a slight increase in arterial pressure and a de crease in rectal temperature were observed. However, these small changes are unlikely to be responsible for the protective effect because smaller doses of AG, which did not alter arterial pressure or rectal temperature, were also effective. Similarly, the decrease in infarct volume is not a consequence of effects of AG on ischemic edema be cause the volume of swelling of the ischemic brain was not influenced by treatment with AG.
It was found that AG was more effective when it was administered 12 or 24 hours after induction of ischemia. This observation suggests that AG counteracts the de layed progression of cerebral ischemic damage that oc curs after MeA occlusion. Recent evidence suggests that the evolution of ischemic brain injury is more protracted in time than previously believed. Histologic data indicate that neuronal damage occurs rapidly in the center of the ischemic territory, whereas at the periphery the damage develops more slowly over days (Garcia et aI., 1995; Garcia et aI., 1993) . Studies by positron emission tomog raphy suggest that brain potentially rescuable from in farction is still present many hours after the onset of ischemia (Furlan et aI., 1996; Marchal et aI., 1996; Tou zani et aI., 1995) . Similarly, studies by magnetic reso nance imaging have shown that the area of irretrievable damage grows over several days after ischemia in pa tients (Baird et aI., 1997) . The mechanisms of the de layed progression of the damage have not been firmly established. Experimental studies indicate that postisch emic expression of iNOS, an enzyme that produces cy totoxic amounts of nitric oxide, contributes to the dam age (Iadecola et aI., 1997; Iadecola, et aI., 1995a,b) . Similarly, expression of cyclooxygenase-2, an enzyme that produces toxic prostanoids and free radicals, may also contribute to the postischemic evolution of the dam age (Nogawa et aI., 1997) . In addition, programmed cell death, a process that develops over days after ischemia, may also participate in the delayed evolution of the dam age (MacManus and Linnik, 1997) . The finding that AG is effective even its administration is delayed by 24 hours after ischemia suggests that AG counteracts some of the factors contributing to the delayed extension of the dam age. However, the time-course of iNOS expression in transient ischemia, produced by intraluminal occlusion of the MCA, is shifted to earlier time points (Iadecola, et aI., 1996) . It is, therefore, likely that the therapeutic win dow will be shorter in transient ischemia than in perma nent ischemia.
There are several mechanisms by which AG could protect the brain from the delayed evolution of the dam age. One possibility is that AG decreases infarct size by inhibiting iNOS activity in the postischemic brain. This hypothesis is supported by several observations. First, AG, at doses comparable to those used in the present study, inhibits calcium-independent NOS activity selec tively in the postischemic brain (Iadecola, et al., 1995a) . Second, the effect of AG is counteracted by co administration of the nitric oxide precursor L-arginine, but not by D-arginine (Iadecola, et aI., 1995a) . Third, the protection exerted by AG is observed during the period when iNOS is expressed in the postischemic brain (Zhang and Iadecola, 1998) . The magnitude of the de crease in infarct size afforded by AG is virtually identical to that observed in null mice lacking the iNOS gene (Iadecola, et aI., 1997) . These observations support the hypothesis that the protective effect exerted by AG is related to iNOS inhibition. However, AG has also other pharmacologic actions that might contribute to its neu roprotective effects. For example, AG is a potent inhibi tor of diamine oxidase (Beaven et aI., 1969) , an enzyme that participates in the degradation of histamine and polyamines (Sessa and Perin, 1994) . The terminal oxi dative deamination of polyamines by diamine oxidase leads to the production of toxic aldehydes (Sessa and Perin, 1994) , compounds that could potentially contrib ute to cerebral ischemic damage. Because increased polyamine synthesis and degradation begins early after an ischemic insult (Paschen et al., 1993) , it is unlikely that, under the experimental conditions of the present study, inhibition of diamine oxidase contributes to the protective effect of AG. Another potential mechanism by which AG could decrease tissues damage is by inhibition of advanced glycation end-products (AGE) production or cross-linking (Brownlee et aI., 1986) . Systemic admin istration of AGE before, but not after ischemia, exacer bates cerebral ischemic damage, an effect that is blocked by AG (Zimmerman et aI., 1995) . However, it has not been shown whether ischemia leads to AGE formation. Therefore, further studies will be required to clarify the role of AGE in cerebral ischemic damage. Irrespective of the mechanisms of the effect, the present results provide additional evidence that delayed administration of AG decreases cerebral ischemic damage. Therefore, this drug could be useful to specifically target the damage that occurs in the late stages of cerebral ischemia.
We also found that AG was less effective when its administration was started 6 hours after ischemia. One possible explanation for this finding is that AG also in hibits endothelial NOS (eNOS) (Laszlo et al., 1995) . The J Cereb Blood Flow Metab, Vol. 18. No. 10. 1998 observation that AG at 400 mg/kg increases arterial pres sure is consistent with the hypothesis that, in our prepa ration, AG inhibits eNOS. Nitric oxide produced by eNOS is beneficial in the early stages of cerebral isch emia, probably, by producing vasodilation and by inhib iting platelet aggregation and leukocyte adhesion (Huang et a\., 1996) . Therefore, eNOS inhibition by AG could result in further flow decrease in regions at risk for in farction and could facilitate postischemic microvascular occlusions by platelets and leukocytes. The worsening of the initial damage resulting from eNOS inhibition could offset the protective effect observed in the late stages of cerebral ischemia. In apparent contradiction with this hy pothesis, however, is the finding that pretreatment or early post-treatment with AG (160 mg/kg) has been re ported to decrease infarct size in a model in which the right common carotid artery is ligated, the right MCA severed, and then the left common carotid artery tran siently occluded in Lewis rats (Cockroft et al., 1996; Zimmerman, et aI., 1995) . Although the reasons for this discrepancy are unclear at the present time, differences in the stroke models, dose of AG, and/or survival times are likely to play a role. Further studies in which the effect of AG on CBF in the early postischemic period is deter mined would help define the potential hemodynamic ef fect of AG after induction of ischemia.
In conclusion, we have shown that AG decreases isch emic cerebral damage and enhances neurologic recovery in a dose-dependent fashion. Delayed treatment is more beneficial than early treatment. The data suggest that AG counteracts the delayed progression of cerebral ischemic damage that occurs in the postischemic period. The fact that AG is effective when administered 12 to 24 hours after induction of cerebral ischemia indicates that this drug could be very valuable in the treatment of human stroke by specifically targeting the late stage of the dam age.
